Fusion Pharmaceuticals (FUSN) just unveiled an update.
On June 4, 2024, Fusion completed a significant transaction, becoming a wholly-owned indirect subsidiary of its Parent company after the Purchaser acquired all outstanding shares. This corporate move resulted in the cancellation or conversion of various equity instruments such as warrants and options, with holders receiving cash payments or contingent value rights (CVRs) based on specific conditions. Fusion also notified NASDAQ of its share delisting, marking a pivotal change in the company’s control. Subsequently, Fusion’s executive officers and board members stepped down, with new directors appointed, symbolizing a fresh governance chapter. The overall deal amounted to an approximate US$2.4 billion payout by the Purchaser for the acquisition.
For an in-depth examination of FUSN stock, go to TipRanks’ Stock Analysis page.
